Hemosphere Names Patrick Wethington New CEO
“On behalf of our board, I want to thank Doris for her five and a half years of service,” said Edson (Ed) Spencer, Jr., of the Hemosphere board. “Doris successfully led the company through FDA clearance and early commercialization of Hemosphere’s HeRO Vascular Access Device, and she decided now is the appropriate time for different leadership. We wish Doris the best in her future endeavors.”
“Pat brings the experience and skill set to build on Doris’ achievements and continue HeRO’s commercialization success,” Spencer continued. “We will benefit from Pat’s extensive medical device background, commercialization experience and demonstrated leadership qualities.”
Wethington said, “Hemosphere is an exciting company with an impressive history of innovation. I’m honored to join Hemosphere’s talented team. I look forward to leveraging my background and experience to help further establish the HeRO device as the next standard of care for maintaining long-term access for hemodialysis patients with venous outflow obstruction.”
Before joining Hemosphere, Wethington served as global vice president of sales and marketing at Gambro Inc., formerly CHF Solutions, where he oversaw the successful commercialization of CHF’s Aquapheresis Peripheral Ultrafiltration System. Prior to Gambro, Wethington spent 10 years in various sales and marketing leadership positions at St. Jude Medical Endocardial Solutions, Inc. Wethington started his career with CPI Guidant, now part of Boston Scientific, where he held numerous clinical, product development and brand management roles. He has a Bachelor of Arts degree from Clemson University and a Masters of Business Administration from the Carlson School of Management at the University of Minnesota.
The company also announced that Ed Spencer of Affinity Capital Management has taken on the position of lead director for Hemosphere’s board. Spencer has served on the company’s board for two years.
About Hemosphere, Inc.
Hemosphere, Inc., is a leading innovator in the global development and commercialization of technologies that revolutionize care and restore quality-of-life for end-stage renal disease patients with compromised vasculature.
For more information on Hemosphere, Inc., and the HeRO Vascular Access Device, visit the company’s website at www.heroaccess.com.
Contacts
Hemosphere Contacts:
Sue Horvath, Chief Financial Officer, VP Operations and HR Hemosphere, Inc. 952.582.6904 phone 612.554.5686 cell shorvath@hemosphere.net
or
Catherine Claeys Padilla Speer Beardsley 612.455.1719 phone 651.983.4312 cell cclaeys@psbpr.com